Gaucher's Disease - Pipeline Review, H2 2015

Date: August 31, 2015
Pages: 86
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GC6CBB02B6AEN
Leaflet:

Download PDF Leaflet

Gaucher's Disease - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Gaucher's Disease - Pipeline Review, H2 2015’, provides an overview of the Gaucher's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Gaucher's Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gaucher's Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gaucher's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gaucher's Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gaucher's Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gaucher's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Gaucher's Disease Overview
Therapeutics Development
Pipeline Products for Gaucher's Disease - Overview
Pipeline Products for Gaucher's Disease - Comparative Analysis
Gaucher's Disease - Therapeutics under Development by Companies
Gaucher's Disease - Therapeutics under Investigation by Universities/Institutes
Gaucher's Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Gaucher's Disease - Products under Development by Companies
Gaucher's Disease - Products under Investigation by Universities/Institutes
Gaucher's Disease - Companies Involved in Therapeutics Development
Actelion Ltd
Amicus Therapeutics, Inc.
Bioorganic Research and Services S.A.
Biosidus S.A.
Dong-A Socio Group
Genzyme Corporation
greenovation Biotech GmbH
ISU ABXIS Co.,Ltd.
JCR Pharmaceuticals Co., Ltd.
Lixte Biotechnology Holdings, Inc.
Neuraltus Pharmaceuticals, Inc.
Okklo Life Sciences BV
Pharming Group N.V.
Protalix BioTherapeutics, Inc.
The International Biotechnology Center (IBC) Generium
UAB Profarma
Gaucher's Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afegostat tartrate + ERT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ambroxol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-3375 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BNT-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gluco-Cerebosidase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-402671 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiglucerase biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiglucerase biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiglucerase biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiglucerase biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiglucerase biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LB-205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
miglustat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OKL-1014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRX-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher’s disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
taliglucerase alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gaucher's Disease - Recent Pipeline Updates
Gaucher's Disease - Dormant Projects
Gaucher's Disease - Discontinued Products
Gaucher's Disease - Product Development Milestones
Featured News & Press Releases
Sep 02, 2014: Shire’s VPRIV400 units/vial launched in Japan for the improvement of symptoms of Gaucher disease
Jul 04, 2014: Shire’s VPRIV approved in Japan for the improvement of symptoms of Gaucher disease
Jun 18, 2014: Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Mar 14, 2014: Shire Pharmaceuticals Initiates Voluntary Nationwide Recall Of One Batch, Packaged into Three Lots, of VPRIV (velaglucerase alfa for injection)
Feb 14, 2014: Shire Announces FDA Approval of Manufacturing Facility for VPRIV (Velaglucerase Alfa for Injection) Drug Substance
Feb 12, 2014: Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014
Oct 14, 2013: Protalix BioTherapeutics Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients
Apr 02, 2013: Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112
Mar 07, 2013: Protalix BioTherapeutics Receives Approval From Israeli Ministry Of Health To Initiate Phase I Clinical Trial Of PRX-112 For Treatment Of Gaucher Disease
Jun 28, 2012: Shire’s Vpriv Shows Significant Improvement In Gaucher-Related Bone Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Gaucher's Disease, H2 2015
Number of Products under Development for Gaucher's Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Gaucher's Disease - Pipeline by Actelion Ltd, H2 2015
Gaucher's Disease - Pipeline by Amicus Therapeutics, Inc., H2 2015
Gaucher's Disease - Pipeline by Bioorganic Research and Services S.A., H2 2015
Gaucher's Disease - Pipeline by Biosidus S.A., H2 2015
Gaucher's Disease - Pipeline by Dong-A Socio Group, H2 2015
Gaucher's Disease - Pipeline by Genzyme Corporation, H2 2015
Gaucher's Disease - Pipeline by greenovation Biotech GmbH, H2 2015
Gaucher's Disease - Pipeline by ISU ABXIS Co.,Ltd., H2 2015
Gaucher's Disease - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015
Gaucher's Disease - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Gaucher's Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2015
Gaucher's Disease - Pipeline by Okklo Life Sciences BV, H2 2015
Gaucher's Disease - Pipeline by Pharming Group N.V., H2 2015
Gaucher's Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
Gaucher's Disease - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
Gaucher's Disease - Pipeline by UAB Profarma, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Gaucher's Disease Therapeutics - Recent Pipeline Updates, H2 2015
Gaucher's Disease - Dormant Projects, H2 2015
Gaucher's Disease - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Gaucher's Disease, H2 2015
Number of Products under Development for Gaucher's Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED
Actelion Ltd
Amicus Therapeutics, Inc.
Bioorganic Research and Services S.A.
Biosidus S.A.
Dong-A Socio Group
Genzyme Corporation
greenovation Biotech GmbH
ISU ABXIS Co.,Ltd.
JCR Pharmaceuticals Co., Ltd.
Lixte Biotechnology Holdings, Inc.
Neuraltus Pharmaceuticals, Inc.
Okklo Life Sciences BV
Pharming Group N.V.
Protalix BioTherapeutics, Inc.
The International Biotechnology Center (IBC) Generium
UAB Profarma
Skip to top


Alzheimer's Disease - Pipeline Review, H2 2016 US$ 2,500.00 Aug, 2016 · 1284 pages
Huntington's Disease - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 311 pages

Ask Your Question

Gaucher's Disease - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: